Walmart, in one of their worst ways of prioritizing prices above qualities to date, turns to a foreign drug supplier, Ranbaxy Laboratories, LTD, who has repeatedly been investigated by the FDA and the DoJ for "inadequate" safeguards against contamination, falsification of records and submitting false information to the FDA.
On top of that, just eight months before the FDA inspected Ranbaxy's Paonta Sahib plant and found significant violations, Walmart awarded the company a "Supplier Award" for improving shipping times and performance.
In a new report on our website, we detail their multi-year spanning violations, DoJ investigation, Congressional Investigation, and list out all of the drugs made at the facility in questions. Additionally, we detail their recent violations below.
India would like to expand its nuclear weapons program, and Joe Lieberman think it's a terrific idea. Lieberman, during a three-day visit to India, endorsed the Bush Administration's position on India's nukes when he said:
"I will do everything I can to help see [the U.S.-India nuclear deal] through the United States Senate.''
Most of the world shudders at the thought of nuclear proliferation in India and the likely arms race that will ensue with India's neighbors China and Pakistan, as well as with Iran. In fact, the U.S. used to have the same concerns as the rest of the world, until recently:
The pact reverses three decades of American policy by allowing the U.S. to send atomic fuel and technology to India, which has never signed international nonproliferation accords and has tested atomic weapons in the past.
[...]
American critics worry about the lack of a test ban and say the deal will stymie U.S. anti-proliferation efforts, especially in Iran, by rewarding India for refusing to sign the Nuclear Nonproliferation Treaty. Iran has signed the accord.
Walmart, in one of their worst ways of prioritizing prices above qualities to date, turns to a foreign drug supplier, Ranbaxy Laboratories, LTD, who has repeatedly been investigated by the FDA and the DoJ for "inadequate" safeguards against contamination, falsification of records and submitting false information to the FDA.
MLN is powered by